CN103732247A - 用于加工含有活细胞的生物药物的方法 - Google Patents

用于加工含有活细胞的生物药物的方法 Download PDF

Info

Publication number
CN103732247A
CN103732247A CN201280032760.XA CN201280032760A CN103732247A CN 103732247 A CN103732247 A CN 103732247A CN 201280032760 A CN201280032760 A CN 201280032760A CN 103732247 A CN103732247 A CN 103732247A
Authority
CN
China
Prior art keywords
living cells
cells
cell
buffer
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280032760.XA
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈-诺伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Priority to CN201810178504.0A priority Critical patent/CN108261423B/zh
Publication of CN103732247A publication Critical patent/CN103732247A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/148—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
CN201280032760.XA 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法 Pending CN103732247A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810178504.0A CN108261423B (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161481991P 2011-05-03 2011-05-03
US61/481,991 2011-05-03
US201161528493P 2011-08-29 2011-08-29
US61/528,493 2011-08-29
US201161565225P 2011-11-30 2011-11-30
US61/565,225 2011-11-30
US201261582878P 2012-01-04 2012-01-04
US61/582,878 2012-01-04
PCT/US2012/036103 WO2012151266A1 (en) 2011-05-03 2012-05-02 Methods for handling biological drugs containing living cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810178504.0A Division CN108261423B (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Publications (1)

Publication Number Publication Date
CN103732247A true CN103732247A (zh) 2014-04-16

Family

ID=47108026

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280032760.XA Pending CN103732247A (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法
CN201810178504.0A Active CN108261423B (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810178504.0A Active CN108261423B (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Country Status (17)

Country Link
US (4) US10350242B2 (enExample)
EP (1) EP2704741B1 (enExample)
JP (3) JP5934783B2 (enExample)
KR (3) KR20140099328A (enExample)
CN (2) CN103732247A (enExample)
AU (1) AU2012250794B2 (enExample)
BR (1) BR112013028257B1 (enExample)
CA (1) CA2838041C (enExample)
DK (1) DK2704741T3 (enExample)
ES (1) ES2648136T3 (enExample)
HU (1) HUE034995T2 (enExample)
IL (1) IL229176B (enExample)
PH (1) PH12013502253A1 (enExample)
PL (1) PL2704741T3 (enExample)
PT (1) PT2704741T (enExample)
SG (1) SG194774A1 (enExample)
WO (1) WO2012151266A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
JP6814593B2 (ja) * 2016-10-14 2021-01-20 株式会社 バイオミメティクスシンパシーズ 幹細胞及び投与システム
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
JP2022519154A (ja) * 2018-12-07 2022-03-22 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド 免疫療法のための組成物および方法
JP2022533949A (ja) * 2019-05-15 2022-07-27 ステムサイト インコーポレーテッド 高濃度細胞のパッケージングおよび輸送
JP7722390B2 (ja) 2020-12-10 2025-08-13 Ａｇｃ株式会社 オキシアルキレン重合体、その製造方法、硬化性組成物、硬化物
JPWO2022191084A1 (enExample) 2021-03-12 2022-09-15
WO2023282298A1 (ja) 2021-07-07 2023-01-12 Ａｇｃ株式会社 硬化性組成物、硬化物、接着剤、及びシーリング材
WO2023190640A1 (ja) * 2022-03-30 2023-10-05 株式会社カネカ 細胞投与用シリンジを調製する方法、及び細胞投与用シリンジを用いた細胞輸送方法
WO2023204067A1 (ja) 2022-04-22 2023-10-26 Ａｇｃ株式会社 硬化性組成物及びその硬化物
JPWO2023204064A1 (enExample) 2022-04-22 2023-10-26
WO2023210586A1 (ja) 2022-04-27 2023-11-02 Ａｇｃ株式会社 反応性ケイ素基含有有機重合体の製造方法
CN119072502A (zh) 2022-04-27 2024-12-03 Ａｇｃ株式会社 含反应性硅基团的有机聚合物的制造方法
CN119301211A (zh) 2022-06-03 2025-01-10 Ａｇｃ株式会社 粘接剂组合物及物品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
WO2005001074A1 (en) * 2003-05-13 2005-01-06 Michael Har-Noy Allogeneic cell therapy: mirror effect
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
AU720201B2 (en) 1995-03-08 2000-05-25 Scripps Research Institute, The Antigen presenting system and methods for activation of T-cells
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
WO1997046256A1 (en) 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU743855B2 (en) * 1996-10-11 2002-02-07 Regents Of The University Of California, The Cancer immunotherapy using tumor cells combined with mixed lymphocytes
WO1998024483A2 (en) 1996-12-03 1998-06-11 Osteobiologics, Inc. Biodegradable polymeric film
US6194207B1 (en) 1997-01-31 2001-02-27 Hemosol Inc. Methods for the selective expansion of lymphocytes by in vitro cultivation
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
ATE412383T1 (de) 1997-05-30 2008-11-15 Osteobiologics Inc Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung
AU1395499A (en) 1997-11-10 1999-05-31 Arch Development Corporation Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells
JP2001054563A (ja) 1999-07-12 2001-02-27 Isotis Bv 縫合糸
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2002017935A2 (en) 2000-08-31 2002-03-07 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
US20040258661A1 (en) 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
US7105580B2 (en) 2001-12-06 2006-09-12 University Of Washington Porous structures useful for growing living tissue, and methods of manufacture
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
EP1776583A4 (en) 2004-02-26 2009-04-29 Immunovative Therapies Ltd PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
CA2530514C (en) 2004-03-01 2017-01-31 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
CA2557436A1 (en) 2004-03-05 2005-09-29 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
CN101965195A (zh) * 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
WO2005001074A1 (en) * 2003-05-13 2005-01-06 Michael Har-Noy Allogeneic cell therapy: mirror effect
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUBEL K ET AL: "Effect storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor", 《TRANSFUSION》, vol. 45, no. 12, 31 December 2005 (2005-12-31), pages 1876 - 1889 *
M D PARKINS ET AL: "Overnight storage of autologous stem cell apheresis products before cryopreservation dose not adversely impact early or long-term engraftment following transplantation", 《BONE MARROW TRANSPLANTATION》, vol. 38, no. 9, 18 September 2006 (2006-09-18), pages 609 - 614 *

Also Published As

Publication number Publication date
JP5934783B2 (ja) 2016-06-15
CN108261423A (zh) 2018-07-10
AU2012250794A8 (en) 2013-12-19
US11648273B2 (en) 2023-05-16
HK1254754A1 (zh) 2019-07-26
CA2838041A1 (en) 2012-11-08
IL229176A0 (en) 2013-12-31
CN108261423B (zh) 2021-01-08
JP2014517830A (ja) 2014-07-24
PT2704741T (pt) 2017-11-24
EP2704741B1 (en) 2017-08-23
DK2704741T3 (da) 2017-11-27
KR20190090030A (ko) 2019-07-31
US20130101562A1 (en) 2013-04-25
US10350242B2 (en) 2019-07-16
EP2704741A1 (en) 2014-03-12
JP2017039728A (ja) 2017-02-23
CA2838041C (en) 2018-09-25
HUE034995T2 (en) 2018-05-02
JP2015091848A (ja) 2015-05-14
ES2648136T3 (es) 2017-12-28
KR20140099328A (ko) 2014-08-11
US20190350976A1 (en) 2019-11-21
KR102202460B1 (ko) 2021-01-14
BR112013028257A2 (pt) 2017-01-17
US20230226112A1 (en) 2023-07-20
WO2012151266A1 (en) 2012-11-08
US20230218672A1 (en) 2023-07-13
JP6006288B2 (ja) 2016-10-12
PL2704741T3 (pl) 2018-02-28
KR20140043367A (ko) 2014-04-09
EP2704741A4 (en) 2014-11-19
KR102229108B1 (ko) 2021-03-18
SG194774A1 (en) 2013-12-30
JP6359059B2 (ja) 2018-07-18
IL229176B (en) 2020-03-31
BR112013028257B1 (pt) 2020-05-12
PH12013502253A1 (en) 2019-11-29
AU2012250794B2 (en) 2015-11-05
AU2012250794A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
US20230218672A1 (en) Methods for handling biological drugs containing living cells
US11013770B1 (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TWI682996B (zh) 處理含有活細胞之生物藥物的方法
HK1254754B (zh) 用於加工含有活细胞的生物药物的方法
HK1195873A (en) Methods for handling biological drugs containing living cells
HK40039382B (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195873

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20140416

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1195873

Country of ref document: HK